VivoSim Labs, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
VivoSim Labs, Inc. (VIVS) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$19.02 million for the 12-month period ending 2018-03-31, per its 10-K filed 2018-05-31.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-05-31
- VivoSim Labs, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was -$3.61M.
- VivoSim Labs, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was -$3.39M, a 118.57% decline year-over-year.
- VivoSim Labs, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was -$4.24M.
- VivoSim Labs, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was -$7.78M.
- VivoSim Labs, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2018 was -$19.02M, a 2982.58% decline from fiscal 2017.
- VivoSim Labs, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $660.00K, a 94.48% decline from fiscal 2016.
- VivoSim Labs, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $11.95M, a 505.01% increase from fiscal 2015.
- VivoSim Labs, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $1.98M, a 93.93% decline from fiscal 2014.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 3 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 21 month | Cash and Cash Equivalents, Period Increase (Decrease) 24 month | Cash and Cash Equivalents, Period Increase (Decrease) 59 month | Cash and Cash Equivalents, Period Increase (Decrease) 62 month | Cash and Cash Equivalents, Period Increase (Decrease) 65 month | Cash and Cash Equivalents, Period Increase (Decrease) 68 month | Cash and Cash Equivalents, Period Increase (Decrease) 71 month | Cash and Cash Equivalents, Period Increase (Decrease) 74 month | Cash and Cash Equivalents, Period Increase (Decrease) 77 month | Cash and Cash Equivalents, Period Increase (Decrease) 80 month | Cash and Cash Equivalents, Period Increase (Decrease) 83 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2018-03-31 | -$3.61M derived: 10-K 12 month − 10-Q 9 month · filed 2018-05-31 | -$7.01M derived: sum of 2 quarters · filed 2018-05-31 | -$11.25M derived: sum of 3 quarters · filed 2018-05-31 | -$19.02M 10-K · filed 2018-05-31 | ||||||||||||
| 2017-12-31 | -$3.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-02-08 | -$7.64M derived: sum of 2 quarters · filed 2018-02-08 | -$15.41M 10-Q · filed 2018-02-08 | -$22.66M derived: sum of 4 quarters · filed 2018-05-31 | ||||||||||||
| 2017-09-30 | -$4.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-11-09 | -$12.02M 10-Q · filed 2017-11-09 | -$19.26M derived: sum of 3 quarters · filed 2018-05-31 | -$991.00K derived: sum of 4 quarters · filed 2018-05-31 | ||||||||||||
| 2017-06-30 | -$7.78M 10-Q · filed 2017-08-09 | -$15.02M derived: sum of 2 quarters · filed 2018-05-31 | $3.25M derived: sum of 3 quarters · filed 2018-05-31 | $1.44M derived: sum of 4 quarters · filed 2018-05-31 | ||||||||||||
| 2017-03-31 | -$7.25M derived: 10-K 12 month − 10-Q 9 month · filed 2018-05-31 | $11.03M derived: sum of 2 quarters · filed 2018-05-31 | $9.21M derived: sum of 3 quarters · filed 2018-05-31 | $660.00K 10-K · filed 2018-05-31 | ||||||||||||
| 2016-12-31 | $18.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-02-08 | $16.46M derived: sum of 2 quarters · filed 2018-02-08 | $7.91M 10-Q · filed 2018-02-08 | -$30.00K derived: sum of 4 quarters · filed 2018-05-31 | ||||||||||||
| 2016-09-30 | -$1.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-11-09 | -$10.37M 10-Q · filed 2017-11-09 | -$18.30M derived: sum of 3 quarters · filed 2018-05-31 | -$25.14M derived: sum of 4 quarters · filed 2018-05-31 | ||||||||||||
| 2016-06-30 | -$8.55M 10-Q · filed 2017-08-09 | -$16.49M derived: sum of 2 quarters · filed 2018-05-31 | -$23.32M derived: sum of 3 quarters · filed 2018-05-31 | -$32.46M derived: sum of 4 quarters · filed 2018-05-31 | ||||||||||||
| 2016-03-31 | -$7.93M derived: 10-K 12 month − 10-Q 9 month · filed 2018-05-31 | -$14.77M derived: sum of 2 quarters · filed 2018-05-31 | -$23.91M derived: sum of 3 quarters · filed 2018-05-31 | $11.95M 10-K · filed 2018-05-31 | ||||||||||||
| 2015-12-31 | -$6.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-02-09 | -$15.97M derived: sum of 2 quarters · filed 2017-02-09 | $19.88M 10-Q · filed 2017-02-09 | $20.00M derived: sum of 4 quarters · filed 2017-06-07 | ||||||||||||
| 2015-09-30 | -$9.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-11-03 | $26.72M 10-Q · filed 2016-11-03 | $26.84M derived: sum of 3 quarters · filed 2017-06-07 | $22.47M derived: sum of 4 quarters · filed 2017-06-07 | ||||||||||||
| 2015-06-30 | $35.86M 10-Q · filed 2016-08-04 | $35.97M derived: sum of 2 quarters · filed 2017-06-07 | $31.61M derived: sum of 3 quarters · filed 2017-06-07 | $41.10M derived: sum of 4 quarters · filed 2017-06-07 | ||||||||||||
| 2015-03-31 | $115.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-06-07 | -$4.25M derived: sum of 2 quarters · filed 2017-06-07 | $5.25M derived: sum of 3 quarters · filed 2017-06-07 | $1.98M 10-K · filed 2017-06-07 | ||||||||||||
| 2014-12-31 | -$4.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-02-08 | $5.13M derived: sum of 2 quarters · filed 2016-02-08 | $1.86M 10-Q · filed 2016-02-08 | $209.00K derived: sum of 4 quarters · filed 2016-06-09 | ||||||||||||
| 2014-09-30 | $9.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-11-09 | $6.22M 10-Q · filed 2015-11-09 | $4.57M derived: sum of 3 quarters · filed 2016-06-09 | $1.03M derived: sum of 4 quarters · filed 2016-06-09 | ||||||||||||
| 2014-06-30 | -$3.27M 10-Q · filed 2015-08-10 | -$4.92M derived: sum of 2 quarters · filed 2016-06-09 | -$8.46M derived: sum of 3 quarters · filed 2016-06-09 | $32.05M derived: sum of 4 quarters · filed 2016-06-09 | ||||||||||||
| 2014-03-31 | -$1.65M derived: 10-K 12 month − 10-Q 9 month · filed 2016-06-09 | -$5.19M derived: sum of 2 quarters · filed 2016-06-09 | $35.32M derived: sum of 3 quarters · filed 2016-06-09 | $32.54M 10-K · filed 2016-06-09 | $48.17M 10-K · filed 2014-06-10 | |||||||||||
| 2013-12-31 | -$3.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-02-06 | $36.97M derived: sum of 2 quarters · filed 2015-02-06 | $34.19M 10-Q · filed 2015-02-06 | $35.00M derived: sum of 4 quarters · filed 2015-06-09 | $49.82M 10-Q · filed 2014-02-06 | |||||||||||
| 2013-09-30 | $40.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-11-07 | $37.73M 10-Q · filed 2014-11-07 | $38.54M derived: sum of 3 quarters · filed 2015-06-09 | $45.68M derived: sum of 4 quarters · filed 2015-06-09 | $53.36M 10-Q · filed 2013-11-08 | |||||||||||
| 2013-06-30 | -$2.78M 10-Q · filed 2014-08-08 | -$1.97M derived: sum of 2 quarters · filed 2015-06-09 | $5.17M derived: sum of 3 quarters · filed 2015-06-09 | $4.38M derived: sum of 4 quarters · filed 2015-06-09 | $12.85M 10-Q · filed 2013-08-09 | |||||||||||
| 2013-03-31 | $811.00K 10-K · filed 2015-06-09 | $7.95M derived: sum of 2 quarters · filed 2015-06-09 | $7.16M derived: sum of 3 quarters · filed 2015-06-09 | $5.28M derived: sum of 4 quarters · filed 2015-06-09 | $15.63M 10-KT · filed 2013-05-24 | |||||||||||
| 2012-12-31 | $7.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-02-06 | $6.35M derived: sum of 2 quarters · filed 2014-02-06 | $4.46M 10-Q · filed 2014-02-06 | $14.48M 10-K · filed 2015-06-09 | $14.82M 10-K · filed 2013-03-15 | |||||||||||
| 2012-09-30 | -$793.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-11-08 | -$2.68M 10-Q · filed 2013-11-08 | $7.34M 10-Q · filed 2012-11-14 | $7.34M derived: sum of 4 quarters · filed 2015-06-09 | $7.68M 10-Q · filed 2012-11-14 | |||||||||||
| 2012-06-30 | -$1.88M 10-Q · filed 2013-08-09 | $8.13M 10-Q · filed 2012-08-14 | $8.13M derived: sum of 3 quarters · filed 2015-06-09 | $8.13M derived: sum of 4 quarters · filed 2015-06-09 | $8.47M 10-Q · filed 2012-08-14 | |||||||||||
| 2012-03-31 | $10.01M 10-K · filed 2015-06-09 | $10.01M 10-Q · filed 2012-05-15 | $10.01M derived: sum of 2 quarters · filed 2015-06-09 | $10.01M derived: sum of 3 quarters · filed 2015-06-09 | $9.92M derived: sum of 4 quarters · filed 2015-06-09 | $10.35M 10-Q · filed 2012-05-15 | ||||||||||
| 2011-12-31 | -$375.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-01-17 | -$1.02K 10-Q · filed 2012-01-17 | -$89.70K derived: sum of 3 quarters · filed 2012-08-14 | $55.00K 10-K · filed 2014-06-10 | $753.00 10-Q · filed 2012-01-17 | |||||||||||
| 2011-09-30 | -$647.00 10-Q · filed 2011-10-31 | -$89.32K derived: sum of 2 quarters · filed 2012-08-14 | -$228.84K 10-Q · filed 2012-11-14 | -$293.46K derived: sum of 4 quarters · filed 2012-08-14 | $1.13K 10-Q · filed 2011-10-31 | |||||||||||
| 2011-06-30 | -$88.67K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-14 | -$266.34K 10-Q · filed 2012-08-14 | -$292.81K derived: sum of 3 quarters · filed 2012-08-14 | -$344.96K derived: sum of 4 quarters · filed 2012-08-14 | ||||||||||||
| 2011-03-31 | -$177.67K 10-Q · filed 2012-05-15 | -$204.14K derived: sum of 2 quarters · filed 2012-05-15 | -$256.29K derived: sum of 3 quarters · filed 2012-05-15 | |||||||||||||
| 2010-12-31 | -$26.47K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-01-17 | -$78.62K 10-Q · filed 2012-01-17 | $144.00K 10-KT · filed 2013-05-24 | |||||||||||||
| 2010-09-30 | -$52.15K 10-Q · filed 2011-10-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |